Table 1 Patient characteristics and applied first line therapies
From: Prognostic and predictive value of cathepsin X in serum from colorectal cancer patients
Subjects, n(%) | ||
|---|---|---|
Gender | ||
Female | 105 (39.8) | |
Male | 159 (60.2) | |
Age (years) | ||
70.3, 32.7 - 93.3 (median, range) | 264 (100.0) | |
Localisation | ||
Left-sided colon cancer | 97 (36.7) | |
Right-sided colon cancer | 63 (23.9) | |
Rectal cancer | 104 (39.4) | |
Stage | ||
I | 42 (15.9) | |
II | 73 (27.7) | |
III | 63 (23.9) | |
IV | 69 (26.1) | |
Not staged | 17 (6.4) | |
Administered chemotherapy | Adjuvant Therapy (stages I-III) | Palliative Therapy (stage IV) |
Subjects, n (%) | Subjects, n (%) | |
5-FU | 2 (1.1) | 1 (1.4) |
5-FU + Isovorin | 7 (3.9) | 4 (5.8) |
Irinotecan + 5-FU | 0 (0) | 3 (4.3) |
Oxaliplatin + 5-FU | 7 (3.9) | 2 (2.9) |
Capecitabine | 3 (1.7) | 1 (1.4) |
Oxaliplatin + Capecitabine | 4 (2.2) | 15 (21.7) |
Other | 1 (0.6) | 4 (5.8) |
Unknown | 2 (1.1) | 3 (4.3) |
Total | 26 (14.6) | 33 (47.8) |